Posters
« Back
Tofacitinib Citrate
EP39467
Poster Title: Tofacitinib Citrate
Submitted on 01 Dec 2022
Author(s): Tylor
Affiliations:
Poster Views: 82
View poster »


Poster Information
Abstract: JAKs cannot phosphorylate the cytokine receptors. Consequently, the receptors cannot contact with STATS. These latter are not phosphorylated and activated. Therefore, they cannot translocate to the nucleus. Gene transcription and cytokine production are inhibited.Summary: Tofacitinib citrate inhibits the phosphorylation and activation of JAKs. References: Rakieh, C.; Conaghan, P.G. Tofacitinib for treatment of rheumatoid arthritis. Advances in Therapy, 2013, 30(8):713-726.
Tegtmeyer, K.; et al. Off-label studies on tofacitinib in dermatology: a review. Journal of Dermatological Treatment, 2019, 6485:1-11.
Robert Harrington, Shamma Ahmad Al Nokhatha and Richard Conway. JAK Inhibitors in Rheumatoid Arthritis: An Evidence-Based Review on the Emerging Clinical Data. J Inflamm Res. 2020; 13: 519–531.
https://www.alfa-api.com/products/tofacitinib-citrate.html
Report abuse »
Questions
Ask the author a question about this poster.
Ask a Question »

Creative Commons